Here’s Why (Nasdaq: GLMD) Is Topping Our Watchlist Right Now—Take a Look While It’s Still Early

It's Official: Krypton Street Announces Galmed Pharmaceuticals (Nasdaq: GLMD) As Its Next Potential Breakout Idea For This Morning. Here’s What We Can Tell You—So Far… Just A Few Days Ago, On Friday 3/14/2025, Maxim Group Published A Report With A $12 Target On (GLMD) — Which Suggests An Upside Potential Of Over 597% From Its $1.72 Close. There’s Less Than 1.65M Shares Listed In The Public Float For (GLMD) — Which Could Lead To The Potential For Significant Swings If Demand Begins To Shift. According To Technical Indicators, (GLMD) Appears To Be Entering An Oversold Territory — Which Could Suggest The Potential For A Trend Reversal. Take A Quick Look At Galmed Pharmaceuticals (NASDAQ: GLMD) While It’s Still Early—We Have All Eyes On This One Right Now. March 17, 2025 Dear Reader, Heads up. We’re bringing Galmed Pharmaceuticals (Nasdaq: GLMD) back into focus as our next potential breakout idea for this morning — 3/17/2025. If you’ve been following us for a while, you’ll know that the last time we highlighted (GLMD), it moved approximately 182% in under 24 hours. Given that our last two Sunday Night Profiles showcased a combined 175% (approx.) in moves, we have every reason to believe that (GLMD) could be one to watch closely tomorrow morning. You see, biotech and pharma are some of the most exciting industries, where a single breakthrough can turn an under-the-radar company into a major market player overnight. Galmed Pharmaceuticals (NASDAQ: GLMD) is a clinical-stage biopharmaceutical company focused on liver, metabolic, and fibro-inflammatory diseases.  The company is advancing Aramchol Meglumine, a potential treatment for Primary Sclerosing Cholangitis (PSC) and other fibrotic conditions.  Aramchol, in Phase 3 clinical development, has already demonstrated significant fibrosis improvement in patients with NASH and fibrosis, as published in Hepatology.  As the most advanced SCD-1 downregulator in clinical trials, Aramchol continues to show potential in multiple therapeutic areas. Learn more here. On Friday, 3/14/2025, Maxim Group published a report which listed Galmed Pharmaceuticals (Nasdaq: GLMD) with a $12 target, which suggests an upside potential of over 597% from its $1.72 close. Here’s 3 Reasons Why Galmed Pharmaceuticals (Nasdaq: GLMD) Is Topping Our Watchlist This Morning… 1. Analyst Coverage: Just a few days, on Friday 3/14/2025, Maxim Group published a report with a $12 target on (GLMD), which suggests an upside potential of over 597% from its $1.72 close. 2. Ultra Low Float: There’s less than 1.65M shares listed in the public float for (GLMD). This limited float could lead to the potential for significant swings if demand begins to shift. 3. Technical Indicators: According to technical indicators found on Barchart, (GLMD) appears to be entering an oversold territory, which could suggest the potential for a trend reversal. Consider Adding Galmed Pharmaceuticals (Nasdaq: GLMD)  to Your Radar Today… When a profile like this starts catching momentum, things can move fast—we’ve seen it happen before. Consider taking a look at (GLMD) while it’s still early. (GLMD) is at the top of our screens right now. Remember— the last time we covered (GLMD), it moved approximately 182% in less than 24 hours.  Keep a lookout for my next update—it could be out very shortly. Sincerely, Alex Ramsay Co-Founder / Managing Editor Krypton Street Newsletter KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KryptonStreet is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of Media 1717 LLC owns and operates kryptonstreet . com (“KS”). From time to time, KS will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: kryptonstreet.com/disclaimer/ *Media 1717 LLC has not been compensated for the March 16th and 17th, 2025's profile on (GLMD:US). Neither Media 1717 LLC, TD Media LLC and their member own shares of (GLMD:US).

Media 1717 LLC | 6586 W Atlantic Ave Unit #2086 | Delray Beach, FL 33446 US Unsubscribe | Update Profile | Constant Contact Data Notice